Introduction
P53 modulates a number of cellular responses to genotoxic stress including cell cycle arrest and apoptosis Shimamura and Fisher, 1996) . Loss of p53 function either by mutation or otherwise may alter the sensitivity of cells to DNA damage (Brown, 1993) . The p53 protein is a complex molecule with multiple functional domains ± including those controlling transactivation, oligomerisation and speci®c DNA binding (see reviews and references therein: Deppert, 1994; Harris, 1996; Picksley and Lane, 1994) . Furthermore, dissociation of cell cycle arrest and apoptosis activities has been demonstrated using certain p53 mutants (Rowan et al., 1996) . The design of low molecular mass modi®ers of the p53 response based on protein structure is an active area of current research (Anderson and Tegtmeyer, 1995; Hupp et al., 1995) .
Functional domains of a given protein may be identi®ed by expression selection of dominant negative peptides that inhibit the activity of the target protein (Gudkov et al., 1993) . Genetic suppressor elements (GSEs) are short sense-or antisense-orientated gene fragments that produce a phenotypic eect in a cell working as either dominant negative peptides or antisense RNA molecules, respectively (Roninson et al., 1995) . Functional selection of random fragment expression libraries allows for the isolation of discrete biologically active GSEs (Gudkov et al., 1993 (Gudkov et al., , 1994 Holzmayer et al., 1992) .
Cisplatin is an important agent used in the treatment of various tumour types, including those of testicular and ovarian origin (Rosenberg, 1985) . The cytotoxic action of cisplatin has been attributed mainly to induced DNA crosslinks (Sherman and Lippard, 1987; Sorenson and Eastman, 1988) . A dependence on wild type p53 function for cisplatin sensitivity in chemosensitive ovarian tumour cell lines has been previously shown (Anthoney et al., 1996; Brown et al., 1993; Eliopoulos et al., 1995; Vasey et al., 1996) . In particular, transfection of a dominant negative p53 mutant into the intrinsically sensitive human ovarian A2780 cell line confers cross-resistance to multiple DNA damaging agents, including cisplatin (McIlwrath et al., 1994; Vasey et al., 1996) .
In the present study, a library of recombinant retroviruses, expressing random fragments of TP53 cDNA, was introduced into A2780 cells and resulting clones selected on the basis of cisplatin resistance. It was predicted that cisplatin selection would enrich for GSEs which could abrogate the endogenous p53-mediated DNA damage response pathway. Our aim was to identify small molecules (dominant negative peptides or antisense RNA) derived from p53 which allow modi®cation of the p53 response to genotoxic stress.
Results

Isolation of GSEs from TP53 cDNA conferring cisplatin resistance
We have constructed libraries of 70 000 and 40 000 recombinant clones containing 50 ± 500 bp fragments from human and murine TP53 cDNA plasmids, respectively. These libraries were generated by random fragmentation of the TP53 plasmids with DNaseI with each fragment inserted between HindIII/ClaI sites within the pLNCX retroviral expression vector, using asymmetrical adaptors which provide translational initiation and termination sites and allow for orientated cloning (Gudkov et al., 1993) . Both plasmid libraries were transfected into the murine amphotropic virus packaging PA317 cell line (Miller and Buttimore, 1986) . Retroviral particles were collected and used to infect human ovarian adenocarcinoma A2780 cells. Most of the infected clones were expected to contain only one copy of the integrated provirus (Con, 1990) .
After infection, G418-resistant colonies of A2780 cells were pooled and subjected to cisplatin selection. We have shown previously that cisplatin resistant mutants can be isolated from A2780 cells using a single step selection protocol (McLaughlin et al., 1991) . Treatment of pLNCX alone A2780 infectants with 12.5 mM cisplatin for 24 h gave a frequency of 2610 75 surviving colonies/viable cell. Pools of A2780 cells infected with diering populations of either human or murine TP53 recombinant viruses were selected at the same drug exposure. Frequencies of surviving colonies/ viable cell were observed in the range 7 to 56610 75 , representing a four-to 29-fold increase in the number of cisplatin resistant colonies induced by the TP53 recombinant libraries. PCR analysis of the integrated proviral elements within A2780 infectants showed enrichment for speci®c DNA fragments after cisplatin selection (data not shown).
These discrete PCR-ampli®ed fragments from cisplatin selected A2780 cells were recloned into the pLNCX vector in the same position and orientation as the primary construct. Sequence analysis revealed that subcloned inserts were derived from TP53 cDNA. It is worth noting that less than 20% of the original plasmid libraries contained p53 inserts (the remainder being from the vector constructs). These observations show that cisplatin selection of A2780 cells infected with either library enriched for TP53-derived GSEs.
The orientation and position of the six TP53-derived GSEs isolated are shown in Table 1 and Figure 1 . The four antisense-orientated GSEs were clustered around the central region of the TP53 gene (nucleotides 361 ± 680). The sense-orientated element GSE1 was predicted to encode a short 17 amino acid peptide containing 11 amino acids of the human p53 protein (300 ± 310) plus amino acids derived from the outlying adaptor sequences. This is derived from an uncharacterised`linker' region found between sequence speci®c DNA binding and oligomerisation domains and is adjacent to a cyclin dependent kinase site (Bischo et al., 1990) . The predicted peptide sequence from the putative element GSE6 (amino acids 251 ± 279) was localised to a portion of the sequence speci®c DNA binding domain (Cho et al., 1994) . Interestingly, most of the GSEs derived from murine TP53 cDNA converged upon areas which contain highly conserved regions of homology (II ± V) (Soussi et al., 1990) . This might be expected considering the GSEs of murine origin were selected in a human cell background.
Induction of cisplatin resistance in A2780 cells by p53 GSEs
The ability of the molecularly isolated GSE clones to confer cisplatin resistance was evaluated by colony formation and growth inhibition assays. A2780 cells Deppert, 1994; Harris, 1996; Picksley and Lane, 1994) were transfected with individual plasmid clones (GSE1 ± 5) and pools of G418-resistant colonies isolated. Table 2 shows the relative levels of resistance to cisplatin for A2780 GSE transfectants. GSE-carrying cells were more resistant than cells with insert-free provirus (1.2 ± 2.9-fold by clonogenic assay). These levels are comparable with the 2 ± 3-fold increase in cisplatin resistance observed by clonogenic assay when a dominant negative p53 mutant is introduced into the same cell line (Vasey et al., 1996) . The higher fold resistance measurements obtained using the MTT cell viability assay (1.5 ± 8.2-fold) may re¯ect cytostatic eects on cell growth induced by cisplatin. These results demonstrate that the isolated p53 GSEs conferred cisplatin resistance in A2780 cells. It is important to note that these phenotypic eects were observed with mass populations of transfectant cells, thus obviating the problems associated with clonal variability (although possibly reducing the potential fold resistance measurements which may have been observed in clonal isolates).
Abrogation of p53-mediated DNA damage response pathway
Ultimately, the inhibitory activity of antisense RNA is mediated by downregulation of protein expression (Denhardt, 1992; Takayama and Inouye, 1990) . Western blot analysis revealed that antisense GSE transfectants (GSE3 ± 5) contained 0.4 ± 0.5-fold lower levels of p53 protein relative to vector alone cells (Table 2 and Figure 2 ). These results suggest that the induction of cisplatin resistance in A2780 cells by antisense GSEs was conferred by loss of p53 function through reduced levels of the protein. It is worth noting that reintroduction of GSE2 did not significantly aect cisplatin resistance or the level of p53 protein in A2780 cells (Table 2 ). This may represent either inadequate expression in transfectant cells or the biological ineectiveness of this particular GSE. The induced resistance to cisplatin and reduction in the steady-state level of p53 protein caused by expression of the antisense p53 GSEs further con®rms the association between loss of p53 function and cisplatin resistance in these human ovarian tumour cells Eliopoulos et al., 1995) . The sense-orientated GSEs were not anticipated to modulate p53 protein synthesis but work by encoding dominant negative mutant peptides (Roninson et al., 1995) . These peptides may inactivate p53 function in a variety of ways, perhaps by interference with modular activities such as sequence speci®c DNA binding or oligomerisation (Herskowitz, 1987) . We observed that GSE1-carrying cells contained increased levels of p53 protein (1.5-fold) compared to vector alone controls (Table 2 ). This may re¯ect stabilisation of endogenous p53 protein through interaction with the GSE1-derived peptide.
Radiation induced G1 arrest has been shown to be dependent on wild-type p53 function in A2780 cells (McIlwrath et al., 1994) . Vector alone A2780 transfectants displayed a functional G 1 arrest after irradiation, as measured by inhibition of replicative DNA synthesis ( Figure 3a and Table 3 ). This inhibition was partially abrogated in a pool of GSE1 transfectants, suggesting that the p53 protein was inactivated in these cells albeit marginally. In an eort to quantitate cisplatin-induced apoptosis,¯ow cytometric detection of DNA strand breaks was achieved usinḡ uorescent (FITC) end-labelling by terminal transferase ( Figure 3b and Table 3 ). After cisplatin treatment, we observed a 2.3-fold reduction in the fraction of FITC-positive GSE1 transfectants compared to vector alone controls. This demonstrates that GSE1-carrying cells engaged apoptosis less readily than vector alone cells in response to cisplatin. Overall, these results suggest that p53 function is revoked by the senseorientated GSE. No dissociation of cell cycle arrest and apoptosis activities was observed with this GSE.
PEP1-F, a synthetic peptide representing the predicted 17 amino acid sequence encoded by GSE1, induced resistance to cisplatin when introduced into A2780 cells by liposome-mediated transfer (Figure 4a) . A control peptide (PEP1-R), which has the same amino acid composition but in reverse order, did not modulate the sensitivity of A2780 cells to drug treatment. The eect on cisplatin resistance mediated Increase in FITC represents¯uorescent labelling of strand breaks by terminal transferase. DNA was stained with propidium iodide. Cells were treated with 40 mM cisplatin for 1 h and analysed 72 h later A2780 cells only occurs 24 h after treatment with cisplatin McIlwrath, Gallagher and Brown, unpublished data) . This may be the critical time point for inhibition of p53 function with PEP1-F. Wild-type p53 protein has a cryptic sequence speci®c DNA binding function which can be activated in vitro by a variety of modi®cations including deletion of the C-terminus (Hansen et al., 1996; Hupp et al., 1992 Hupp et al., , 1995 . PEP1-F inhibited binding of Baculovirusexpressed human p53 protein to its consensus site in a dose-dependent manner (Figure 4b, top panel) . Maximal inhibition was observed with a 10-fold excess of peptide compared to p53 protein. The control peptide appeared to stimulate DNA binding at high concentrations. Neither peptide aected the ability of a mutant p53 protein (D30), which has the last 30 Cterminal amino acids deleted (Hupp et al., 1992) , to bind speci®cally to its consensus site (Figure 4b , bottom panel). Small basic peptides have been shown to activate the latent sequence-speci®c DNA binding function of p53 (Hupp et al., 1995) . It is possible that the stimulatory activity of the control peptide at high concentrations may be due to non-speci®c involvement of its two basic amino acid residues.
Discussion
Loss of p53 function by transfection of a dominant negative p53 mutant into the intrinsically sensitive human ovarian A2780 cell line has been shown to induce radioresistance and cross-resistance to multiple anticancer drugs, including cisplatin (McIlwrath et al., 1994; Vasey et al., 1996) . We have utilised this phenomenon during the selection of random TP53 cDNA fragments which confer cisplatin resistance in A2780 cells. A number of GSEs have been isolated from both human and murine TP53 cDNA which are in either sense-or antisense-orientation. Each type of GSE induced cisplatin resistance when introduced individually into A2780 cells. Levels of resistance were comparable with those previously observed when a dominant negative p53 mutant is expressed in the same cell line (Vasey et al., 1996) . It is noteworthy that GSEs derived from murine cDNA acted in a human cellular context. This may re¯ect the high degree of evolutionary conservation found in the TP53 gene and/or the potent biological activity of the isolated GSEs (Gudkov et al., 1993) .
All of the antisense-orientated GSEs were derived from the central portion of the TP53 gene (spanning nucleotides 361-680) and this seemingly nonrandom distribution of biological active antisense elements has been previously observed by others (Gudkov et al., 1993) . Antisense oligonucleotides which target p53 expression are currently being used in clinical trials (Bishop et al., 1996) . Such agents are directed against a variety of regions within the TP53 gene, including exon 10 and the translation initiation codon (Bayever et al., 1994; Bi et al., 1994) . However, some concern has been expressed that the phenotypic eect of some antisense oligonucleotides may be unrelated to the gene they have been designed to target (Barton and Lemoine, 1995) . Expression of GSEs encoding antisense RNA in A2780 cells reduced the intracellular level of p53 protein con®rming their inhibitory activity on p53 expression.
Sense-orientated GSEs are of particular interest as indicators of protein domains that are capable of independent functional interactions (Roninson et al., 1995) . It was anticipated that GSE1 would encode a 17 amino acid peptide, containing amino acids 300 ± 310 of the human p53 protein which is localised to a previously uncharacterised`linker' region (Table 1 and Figure 1 ). When expressed in A2780 cells, this GSE reduced p53-mediated activities such as cell cycle arrest and apoptosis in response to DNA damage. An independent study has utilised etoposide resistance or focus formation as selection strategies for the isolation of various sets of GSEs from rat p53 cDNA (Ossovskaya et al., in press ). Interestingly, GSE1 overlaps the region where the most powerful class of GSEs were observed in this study. The isolation of GSE1 allows a more precise identi®cation of the region responsible for inhibition of p53 activity in this class of GSEs.
Liposome-mediated transfer of a synthetic peptide, comprised of the predicted amino acid sequence of GSE1, into A2780 cells conferred resistance to cisplatin. This peptide also inhibited the sequence speci®c DNA binding activity of human p53 protein in vitro. The requirement for the C-terminal regulatory domain of p53 suggests that the peptide may achieve its inhibitory activity by further constraining wild-type p53 protein in a cryptic or latent conformation ( Figure  1 ; Hupp et al., 1992) . These studies directly showed that the sense-orientated p53 GSEs can work as dominant negative mutants.
In cell types permissive for apoptosis, loss of p53 function may mediate increased resistance to anticancer agents which induce DNA damage (Lowe, 1995; Shimamura and Fisher, 1996) . Both sense-and antisense-orientated GSEs induced cisplatin resistance in A2780 cells (which are permissive for p53-dependent apoptosis: McIlwrath, Gallagher and Brown, unpublished data) through abrogation of the p53-mediated DNA damage response pathway by dominant negative interference or reduction in p53 protein levels, respectively. These results indicate a strong association between p53 function and cisplatin resistance in these chemosensitive human ovarian tumour cells.
These results also demonstrated the ecacy of random fragment selection as a combinatorial approach to isolating biologically active p53 GSEs. 
In particular, this is the ®rst example of GSE selection being used to de®ne the sequence of a biologically active synthetic peptide. Several investigators have suggested the possibility of modulating p53 function using small peptides or peptidomimetic drugs (Anderson and Tegtmeyer, 1995; Hupp et al., 1995) . The work presented in this study may have use in the rational design of low molecular mass modi®ers of the p53 response.
Depending upon the genetic context, introduction of dominant negative p53 mutants can have apparently contradictory eects on cellular cisplatin resistance. For example, inactivation of wild-type p53 function in MCF7 cells using a dominant negative p53 mutant conferred increased sensitivity to cisplatin (Fan et al., 1995) . In addition, we have previously observed similar sensitisation eects when the same dominant negative p53 mutant is introduced into a cisplatin resistant Peptides were added to a ®nal concentration of either 1 or 10 mM using liposome-mediated transfer at the same time as cisplatin treatment or 24 h later. Cells were exposed to peptides for 24 h before washing. PEP1-R, solid line and open circles; PEP1-F, broken line and closed circles. Cell viability was determined relative to optical density readings at 570 nm. Curve ®tting was achieved using SigmaPlot 1.02 (Jandel Corporation). Each point represents the mean of four independent determinations with the error bars referring to the s.e.m. Fold resistance measurements (RF) were calculated using the mean IC 50 values obtained from at least three experiments. The ®gures in parenthesis refer to the s.e.m. All calculations were made relative to control peptide A2780 transfectants. A paired Student's t-test was used to compare IC 50 values from individual experiments. (b) Gel mobility shift assay showing activated p53-DNA complexes. All lanes contained excess radiolabelled DNA probe and p53 proteintop (wild-type) and bottom (D30 mutant) panel. Synthetic peptides (PEP1-F and -R) were added to ®nal concentrations indicated ovarian cell line which has abrogated p53 function . Therefore, the PEP1-F peptide may have use in reversing cisplatin resistance in these speci®c genetic backgrounds. Many tumour cells have inactivated p53 function, yet retain wild-type TP53 gene sequence . Using appropriate selection strategies, it may be possible to identify elements from a TP53 retroviral expression vector library which can restore p53 function in such cells.
Materials and methods
Cell lines
The ovarian adenocarcinoma A2780 cell line was originally isolated from an untreated patient and has been shown to express only wild-type p53 sequence and to be relatively sensitive to DNA damaging agents Hamaguchi et al., 1993) . PA317 is an amphotropic virus packaging line derived from NIH/3T3 cells (Miller and Buttimore, 1986) . All cell lines were maintained as monolayers in RPMI 1640 medium with 10% FCS and grown at 378C in 95% air, 5% CO 2 .
Random fragment retroviral expression libraries
Plasmids containing human (Baker et al., 1990) and murine (Arai et al., 1986) TP53 cDNA were randomly fragmented by digestion with DNasel and the resulting termini rendered blunt-ended as previously described (Holzmayer et al., 1992) . DNA fragments of 50 ± 500 bp were ligated with excess amounts of the following synthetic adaptors which provide translational initiation and termination codons:
Adaptor 1 5'-TACCGAATTCAAGCTTATGGATGGATG-3
PCR ampli®ed fragments (using primers derived from the adaptor sequences) were digested with HindIII/ClaI and cloned into the corresponding site of the retroviral expression vector pLNCX (Miller and Rosman, 1989) . Plasmid libraries were generated which comprised of 70 000 and 40 000 independent recombinant clones (490% inserts as determined by HindIII/ClaI digestion and PCR ampli®cation) from human and murine TP53 cDNA plasmids, respectively.
Library transduction and cisplatin selection
PA317 cells were transfected with library DNA or insertfree pLNCX plasmid using a standard calcium phosphate procedure (Wigler et al., 1977) . Viral supernatant was collected from stable G418-resistant transfectants and used to infect A2780 cells. Stable A2780 infectants were seeded at 10 6 /10 cm plate, exposed to 10 ± 20 mM cisplatin for 24 h and left for 10 ± 14 days (plating eciency controls were included). Resistant colonies were picked and expanded.
Identi®cation of GSEs conferring cisplatin resistance
Proviral inserts were recovered from the genomic DNA of cisplatin resistant A2780 infectants by PCR, using primers corresponding to the vector sequences¯anking the inserts: 5'-CCTGGAGACGCCATCCAC-3' (sense) and 5'-AGC-TAGCTTGCCAAACCTA-3' (antisense). PCR products were re-cloned into the pLNCX vector maintaining original orientation of the insert. Subsequent to cloning, inserts were sequenced in both directions using the ABI PRISM Dye Terminator Cycle Sequencing Kit.
Plasmids containing TP53 GSEs were transfected into A2780 cells, G418-resistant colonies were isolated and subjected to cisplatin resistance assays. For clonogenic analysis, cells were seeded at 10 3 /10 cm plate and incubated for 24 h. Following cisplatin treatment (1 h), colonies were grown for 10 ± 14 days then stained with Giemsa. For MTT analysis, cells were seeded in 96-well plates at 500 cells per well and incubated for 3 days. After cisplatin treatment (24 h), medium was replenished three times every 24 h. Relative cell numbers were measured using 3-(4,5-dimethiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide staining as described (Plumb et al., 1989) .
Western blot analysis
Cell extracts were prepared by lysing exponentially growing cells in 1% NP-40, 500 mM NaCl, 50 mM Tris HCl [pH 7.5] and 1 mM DTT in the presence of protease inhibitors. Protein concentrations were determined by the BioRad protein assay. Immunoblotting was performed as described using the anti-p53 mouse MAb (clone DO-1). A loading control was provided by using the antivinculin mouse MAb (clone VIN-11-5). Anti-mouse IgG horseradish-peroxidase-linked rabbit antibody (Amersham) was used as the secondary antibody. Bound complexes were visualised by enhanced chemiluminescence and autoradiography. Autoradiographs were scanned by laser densitometry (Molecular Dynamics) and image analysis carried out using PDQuest software (Protein Databases Inc.)
Cell cycle assay DNA synthesis was assessed by incorporation of bromodeoxyuridine (BrdUrd) and¯ow cytometric analysis essentially as previously described (Kastan et al., 1991) . Exponentially growing cells were plated at 5610 5 /10 cm plate in growth medium and incubated for 3 days. Cells were irradiated with g-rays from a 60 Co source. After 24 h, the growth medium was replaced by medium containing 10 mM BrdUrd and the cells were incubated for 4 h at 378C. The cells were ®xed with ethanol, washed with PBS and resuspended in 1 ml 2N HCl for 30 min at room temperature. The partially denatured cells were washed twice in PBS and once in PBS/0.1% Tween-20 (PBT) containing 1.0% BSA and then incubated with an antiBrdUrd mouse MAb (clone Bu20a). The cells were washed with PBT and incubated with anti-mouse IgG¯uorescein 5-isothiocyanate-conjugated (FITC) goat antibody (Sigma). After a further wash in PBT, cells were analysed viā ow cytometry.
Apoptosis assay
Apoptotic cells were detected by¯ow cytometry as described previously (Gorczyca et al., 1993) . Exponentially growing cells were treated with cisplatin and harvested 72 h later. Attached and non-attached cells were collected and ®xed in 1% formaldehyde. Cells were rehydrated in PBS and ®xed again with 70% ethanol (precooled to 7208C). Aliquots of 10 6 cells were incubated for 30 min at 378C with cacodylate buer (0.2 M potassium cacodylate, 2.5 mM Tris HCl [pH 6.6], 2.5 mM CoCl 2 , 0.25 mg/ml BSA, 5 U terminal transferase/10 6 cells. 0.5 nmoles biotin-dUTP/ 10 6 cells). After washing in PBS, cells were incubated for 30 min at room temperature in the dark with 46SSC and 0.1% Triton X-100 containing 5% Marvel and 5 mg/ml FITC-avidin. After a further wash in PBS and 0.1% Triton X-100, cells were analysed by¯ow cytometry.
Flow cytometry
After FITC staining, cells were washed with PBS and resuspended in 10 mg/ml of propidium iodide (PI) in PBS and stored at 48C until analysis. Cellular¯uorescence was measured using a FACScan¯ow cytometer (Becton Dickinson). The red (PI) and green (FITC) emissions from each cell were separated and quanti®ed using the standard optics of the FACScan.
Peptide synthesis
Two peptides were chemically synthesized and puri®ed 495% by HPLC (Aniti Research Products Ltd.). PEP1-F corresponded to the 17 amino acid sequence predicted by the short-sense-orientated element GSE1. A control peptide was created which comprised of the same amino acids but in reverse order.
PEP1-F H-MDVPPGSTKRALPNMSE-OH PEP1-R H-ESMNPLARKTSGPPVDM-OH
Gel mobility shift assay A 25 ml reaction volume contained DNA binding buer (20% glycerol, 25 mM HEPES [pH 7.6], 50 mM KCl, 0.1% Triton X-100, 1 mM dithiothreitol and 1 mg/ml BSA) mixed with combinations of Baculovirus-expressed human p53 protein (Hansen et al., 1996) , radiolabelled oligonucleotide probe (comprised of the p53 DNA binding consensus site: El-Deiry et al., 1992) and synthetic peptide. After incubation on ice for 30 min, reaction products were processed by using native gel electrophoresis as indicated previously (Hupp et al., 1992) .
Liposome-mediated peptide transfer
The synthetic peptides (1 or 10 mM ®nal concentration) were transfected into A2780 cells using the cationic lipid DOTAP (N-[1-(2,3-dioleoyloxy) propyl]N,N,N-trimethylammoniummethylsulfate: Boehringer Mannheim) at 6 mg/ml ®nal concentration. Lipid and peptide mixtures were incubated for 15 min at room temperature, before being added to fresh medium and directly loaded onto cells.
